Abstract
GENERAL COMMENTARY article Front. Neurosci., 19 April 2016Sec. Neurodegeneration https://doi.org/10.3389/fnins.2016.00161
Highlights
Specialty section: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience
This publication is a review on the preclinical model used today for Parkinson’s disease that take in consideration both preclinical model based on neurotoxin or mutations associated to familial Parkinson’s disease (PD)
The question is why successful results in preclinical studies cannot be translated to clinical studies? In our opinion (i) The preclinical models based on exogenous neurotoxins such as 6-hydroxidopamine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) has been very useful and valuable tools to study mechanisms
Summary
Specialty section: This article was submitted to Neurodegeneration, a section of the journal Frontiers in Neuroscience. The use of correct preclinical model to study the mechanisms and to test possible new therapies is essential to obtain successful results and new therapies.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
